ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2014
Accumulation of carbapenem resistance mechanisms in VIM-2-producing Pseudomonas aeruginosa under selective pressure.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 35 citations in OpenAlex.
- Genomic characteristics and risk factor analysis of carbapenem-non-susceptible Pseudomonas aeruginosa causing bacteremia in a tertiary hospital (2014-2023).BMC microbiology · 2026Article
- Genomic analysis of non-carbapenem drug-resistant Gram-negative bacteria from advanced chronic liver disease (ACLD) patients suggests no evidence for in-house transmissions.Frontiers in microbiology · 2025Article
- Efficacy of Imipenem/Cilastatin/Relebactam in infections caused by Difficult-to-Treat Gram-Negative Bacteria: A Retrospective Analysis of Real-world data in Greece.Le infezioni in medicina · 2025Article
- Characterization of carbapenem-resistant Enterobacterales andJournal of clinical microbiology · 2024Article
- Rapid Reversal of Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2024Article
- Jumbo phages are active against extensively drug-resistant eyedrop-associatedAntimicrobial agents and chemotherapy · 2023Article
- Surveillance of Antimicrobial Resistance and Multidrug Resistance Prevalence of Clinical Isolates in a Regional Hospital in Northern Greece.Antibiotics (Basel, Switzerland) · 2023Article
- Replacement of the Double Meropenem Disc Test with a Lateral Flow Assay for the Detection of Carbapenemase-Producing Enterobacterales andAntibiotics (Basel, Switzerland) · 2023Article
- A systematic scoping review of faropenem and other oral penems: treatment of Enterobacterales infections, development of resistance and cross-resistance to carbapenems.JAC-antimicrobial resistance · 2022Article
- JMM Profile: Carbapenems: a broad-spectrum antibiotic.Journal of medical microbiology · 2021Review
- Molecular Surveillance of Carbapenem-Resistant Gram-Negative Bacteria in Liver Transplant Candidates.Frontiers in microbiology · 2021Article
- Eight-year trends in the relative isolation frequency and antimicrobial susceptibility among bloodstream isolates from Greek hospitals: data from the Greek Electronic System for the Surveillance of Antimicrobial Resistance - WHONET-Greece, 2010 to 2017.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2020Observational
- Mechanisms for Rapid Evolution of Carbapenem Resistance in a Clinical Isolate ofFrontiers in microbiology · 2020Article
- In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa.BMC microbiology · 2019Article
- Phenotypic and genotypic detection of antibiotic resistance ofAfrican health sciences · 2018Article
- MULTILOCUS SEQUENCE TYPING OF CARBAPENEM RESISTANTAfrican journal of infectious diseases · 2017Article
- Carbapenem resistance: overview of the problem and future perspectives.Therapeutic advances in infectious disease · 2016Review
- Double- and multi-carbapenemase-producers: the excessively armored bacilli of the current decade.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2015Review
- Role of the Outer Membrane Protein OprD2 in Carbapenem-Resistance Mechanisms of Pseudomonas aeruginosa.PloS one · 2015Article
- Resistance mechanisms and therapeutic strategies forTherapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudomonas aeruginosa has the potential to achieve resistance to carbapenems via the acquisition of carbapenemase-encoding genes, the downregulation of the OprD porin, the overexpression of efflux systems and the overproduction of cephalosporinases. One hundred and fifty carbapenem-non-susceptible isolates from 2008 to 2010 were screened for carbapenemase production, OprD porin loss, efflux pumps overexpression and inducible AmpC beta-lactamase production. For comparison reasons, the presence of the same mechanisms was also assessed in a previous collection of 30 carbapenem-non-susceptible P. aeruginosa isolated between 2003 and 2005. Results showed the accumulation of various resistance mechanisms among VIM-2 producers isolated between 2008 and 2010 with a parallel considerable increase in imipenem MIC90 and the geometric mean of the MIC values of imipenem and meropenem between the two study groups. The accumulation of carbapenem resistance mechanisms highlights the potential of this formidable pathogen for evolutionary success under antibiotic selective pressure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.